Header Logo

Connection

Michael Harrington to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Michael Harrington has written about Antibodies, Monoclonal, Humanized.
Michael Harrington
Connection Strength
0.225
Antibodies, Monoclonal, Humanized
  1. Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial. J Immunother Cancer. 2026 Jan 14; 14(1).
    View in: PubMed
    Score: 0.225
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.